Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Incompetence of SFJ associated with incompetence of the GSV or other major accessory vein~* Ability to comprehend and sign an informed consent document and complete study questionnaires in English~* Ability to record symptoms in accordance with the protocol~* Symptomatic varicose veins~* Visible varicose veins~Exclusion Criteria:~* Patients who only have telangiectatic or reticular veins (Clinical Finding C1, as assessed by CEAP (clinical, etiologic, anatomic, and pathophysiologic) Classification of Venous Disorders).~* Leg obesity impairing the ability to access the vein to be treated and/or to apply postprocedure compression bandaging and stockings~* Ultrasonographic or other evidence of current or previous deep vein thrombosis or occlusion~* Deep vein reflux unless clinically insignificant in comparison to superficial reflux~* Peripheral arterial disease precluding the wearing of post-procedure compression bandaging and stockings~* Reduced mobility~* Major surgery, prolonged hospitalization or pregnancy within 3 months of screening~* Major co-existing disease (e.g. malignancy; pulmonary disease; renal or hepatic insufficiency; serious skin disease/condition that may compromise the ability of the patient to comply with the compression protocol, etc.)~* Known allergic response to polidocanol or heparin, including history of heparin-induced thrombocytopenia, and/or multiple allergic reactions~* Current alcohol or drug abuse~* Pregnant or lactating women~* Women of childbearing potential not using effective contraception~* History of DVT, pulmonary embolism or stroke

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Polidocanol injectable foam 0.125% (Type: EXPERIMENTAL): Polidocanol injectable foam 0.125%
- Polidocanol injectable foam 0.5% (Type: EXPERIMENTAL): Polidocanol injectable foam 0.5%
- Polidocanol injectable foam 1.0% (Type: EXPERIMENTAL): Polidocanol injectable foam 1.0%
- Polidocanol injectable foam 2.0% (Type: EXPERIMENTAL): Polidocanol injectable foam 2.0%
- Vehicle (Type: PLACEBO_COMPARATOR): Injection of vehicle comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).